6 Besides, some of the other key updates include • We submitted our first Communication of Progress (CoP) as a signatory to the United Nations Global Compact (UNGC), showing commitment to sustainability practices • We concluded PSCI audits from innovator pharma customers with no major observations • We joined the ‘Sustainable Markets Initiative’ taskforce as part of Manufacture 2030, with stakeholders to take concrete steps to decarbonise healthcare supply chains • We strengthened sustainability governance by adding clauses on anti-corruption, bribery and anti-money laundering in our Code of Conduct and Ethics Policy • We began monitoring and measuring Scope 3 emissions to increase transparency and visibility of our carbon footprint across the value chain • We set up the ‘Sustainability Governance Council’ to integrate sustainability matters into business strategy and to oversee the enforcement of the sustainability mandate Augmenting capabilities, building partnerships At Sai, we build lasting partnerships with our clients through collaboration. We take a nimble and creative approach to deliver high-quality, cost effective solutions for our biotech and pharma partners to accelerate the time to market. In 2022-23, we concluded Sai Nxt, the 5-year long organization-wide initiative that focused on three key areas -- People & Culture, Processes & Automation and Infrastructure & Scientific capabilities by making a cumulative investment of US $150 million. Sai Nxt has provided us with a perfect platform to propel our growth and we will continue to maintain the momentum by strengthening capabilities. In the reporting year, these are some of the areas where we strengthened our capabilities and forged new partnerships which significantly contribute to the sustainability agenda: • We entered into a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, India. In 100-day, we inaugurated SSRL at our R&D campus in Hyderabad, India. SSRL is a dedicated facility for integrated discovery work streams including medicinal & synthetic chemistry, in vitro biology, and process chemistry • We opened a new High-Potency API (HPAPI) manufacturing facility at our cGMP API manufacturing campus in Bidar, India. The addition of this new facility expands the company’s expertise across HPAPI development and manufacturing, providing our customers with a streamlined pathway for NCE development • We set up a GMP kilo lab at our facility in Alderley Park, Manchester, UK. The new GMP kilo lab will enable Sai to offer drug substance and intermediate supplies ranging from gram to kilogram quantities to meet customer clinical requirements at an accelerated pace • We continued to digitalize our systems & processes. This helped us improve collaborative innovation, increasing productivity and regulatory compliance, reducing safety risks, and accelerating time to market Beyond Science We believe in harmonious coexistence with the local communities and supporting their development as we chart our growth. We work with communities around our sites to identify opportunities for engagement in three priority areas – Education, Health and Livelihood Development. In the reporting year, we added environmental sustainability as a new focus area, and conducted multiple plantation drives to boost the green cover. Besides, we entered into an agreement with NIIT Foundation, a not-for-profit education society, to implement youth career development programs for underserved communities in Hyderabad. Sincerely, Krishna Kanumuri CEO & Managing Director 6
RkJQdWJsaXNoZXIy MTIwMDc4NQ==